🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million instances annually. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This medication, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to findings released by a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This establishes an comparable level with the typical regimen, which combines a dual-drug approach. The research enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced optimism. Having a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered vital to lessen the impact of the disease for people and to halt the transmission of untreatable gonorrhoea globally.